Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years
NCT00563953
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
Liposomal pegylated doxorubicine
Sponsor
SOLTI Breast Cancer Research Group
Collaborators
[object Object]